These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 6804110)

  • 1. Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies.
    DiBianco R; Fletcher RD; Cohen AI; Gottdiener JS; Singh SN; Katz RJ; Bates HR; Sauerbrunn B
    Circulation; 1982 Jun; 65(6):1134-47. PubMed ID: 6804110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of oral encainide in frequent and repetitive ventricular arrhythmias.
    Bongiorni MG; Levorato D; Arlotta C; Paperini L; Contini C
    Eur Heart J; 1988 Jul; 9(7):765-76. PubMed ID: 3139413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
    Caron JF; Libersa CC; Kher AR; Kacet S; Wanszelbaum H; Dupuis BA; Poirier JM; Lekieffre JP
    J Am Coll Cardiol; 1985 Jun; 5(6):1457-63. PubMed ID: 2582017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of antiarrhythmic response to encainide.
    Duff HJ; Roden DM; Carey EL; Wang T; Primm RK; Woosley RL
    Am J Cardiol; 1985 Nov; 56(13):887-91. PubMed ID: 3933319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms.
    Horowitz LN
    Am J Cardiol; 1986 Aug; 58(5):83C-86C. PubMed ID: 3092624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway.
    Kunze KP; Kuck KH; Schlüter M; Kuch B; Bleifeld W
    Am J Cardiol; 1984 Aug; 54(3):323-9. PubMed ID: 6431796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with left ventricular dysfunction. The Encainide-Ventricular Tachycardia Study Group.
    Am J Cardiol; 1988 Sep; 62(9):571-5. PubMed ID: 3137797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiology of oral encainide.
    Jackman WM; Zipes DP; Naccarelli GV; Rinkenberger RL; Heger JJ; Prystowsky EN
    Am J Cardiol; 1982 Apr; 49(5):1270-8. PubMed ID: 6801954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide.
    Winkle RA; Peters F; Kates RE; Harrison DC
    Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias.
    Winkle RA; Peters F; Kates RE; Tucker C; Harrison DC
    Circulation; 1981 Aug; 64(2):290-6. PubMed ID: 6788400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function.
    Sami MH; Derbekyan VA; Lisbona R
    Am J Cardiol; 1983 Sep; 52(5):507-11. PubMed ID: 6412535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome.
    Prystowsky EN; Klein GJ; Rinkenberger RL; Heger JJ; Naccarelli GV; Zipes DP
    Circulation; 1984 Feb; 69(2):278-87. PubMed ID: 6418407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant ventricular tachyarrhythmias associated with the use of encainide.
    Winkle RA; Mason JW; Griffin JC; Ross D
    Am Heart J; 1981 Nov; 102(5):857-64. PubMed ID: 6795909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
    Slater W; Lampert S; Podrid PJ; Lown B
    Am J Cardiol; 1988 Feb; 61(4):349-53. PubMed ID: 3124591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.